Cytokinetics Announces Prescribing Information For MYQORZO Expanded To Include Data From Phase 3 MAPLE-HCM
Nov 16 (Reuters) - Cytokinetics, Incorporated CYTK.O:
CYTOKINETICS ANNOUNCES PRESCRIBING INFORMATION FOR MYQORZO® (AFICAMTEN) EXPANDED TO INCLUDE DATA FROM PHASE 3 MAPLE-HCM
CYTOKINETICS ANNOUNCES PRESCRIBING INFORMATION FOR MYQORZO® (AFICAMTEN) EXPANDED TO INCLUDE DATA FROM PHASE 3 MAPLE-HCM
CYTOKINETICS, INCORPORATED - FDA APPROVES SNDA UPDATING MYQORZO LABEL WITH PHASE 3 MAPLE-HCM DATA
Further company coverage: CYTK.O